.
MergerLinks Header Logo

New Deal


Announced

Flerie Invest to acquire Cobra Biologics from Charles River for $52m.

Synopsis

Flerie Invest, a venture capital firm, agreed to acquire Cobra Biologics, a provider of pharmaceutical and biotechnology research services, from Charles River, a pharmaceutical company, for $52m. “I look forward to working with the highly competent staff in Matfors to help grow innovative biotech companies, and to create security of supply of drugs and vaccines, and so be better prepared for future pandemics,” Ted Fjällman, Flerie Invest Partner.

Show Details & Financials

Market Context

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US